TY - JOUR
T1 - Targeted Dual-Modal PET/SPECT-NIR Imaging
T2 - From Building Blocks and Construction Strategies to Applications
AU - Usama, Syed Muhammad
AU - Marker, Sierra C.
AU - Vargas, Servando Hernandez
AU - Aghaamiri, Solmaz
AU - Ghosh, Sukhen C.
AU - Ikoma, Naruhiko
AU - Cao, Hop S.Tran
AU - Schnermann, Martin J.
AU - Azhdarinia, Ali
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Molecular imaging is an emerging non-invasive method to qualitatively and quantitively visualize and characterize biological processes. Among the imaging modalities, PET/SPECT and near-infrared (NIR) imaging provide synergistic properties that result in deep tissue penetration and up to cell-level resolution. Dual-modal PET/SPECT-NIR agents are commonly combined with a targeting ligand (e.g., antibody or small molecule) to engage biomolecules overexpressed in cancer, thereby enabling selective multimodal visualization of primary and metastatic tumors. The use of such agents for (i) preoperative patient selection and surgical planning and (ii) intraoperative FGS could improve surgical workflow and patient outcomes. However, the development of targeted dual-modal agents is a chemical challenge and a topic of ongoing research. In this review, we define key design considerations of targeted dual-modal imaging from a topological perspective, list targeted dual-modal probes disclosed in the last decade, review recent progress in the field of NIR fluorescent probe development, and highlight future directions in this rapidly developing field.
AB - Molecular imaging is an emerging non-invasive method to qualitatively and quantitively visualize and characterize biological processes. Among the imaging modalities, PET/SPECT and near-infrared (NIR) imaging provide synergistic properties that result in deep tissue penetration and up to cell-level resolution. Dual-modal PET/SPECT-NIR agents are commonly combined with a targeting ligand (e.g., antibody or small molecule) to engage biomolecules overexpressed in cancer, thereby enabling selective multimodal visualization of primary and metastatic tumors. The use of such agents for (i) preoperative patient selection and surgical planning and (ii) intraoperative FGS could improve surgical workflow and patient outcomes. However, the development of targeted dual-modal agents is a chemical challenge and a topic of ongoing research. In this review, we define key design considerations of targeted dual-modal imaging from a topological perspective, list targeted dual-modal probes disclosed in the last decade, review recent progress in the field of NIR fluorescent probe development, and highlight future directions in this rapidly developing field.
KW - Dual-modal imaging
KW - Fluorescence-guided surgery
KW - Heptamethine
KW - PET/SPECT imaging
UR - http://www.scopus.com/inward/record.url?scp=85126979953&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126979953&partnerID=8YFLogxK
U2 - 10.3390/cancers14071619
DO - 10.3390/cancers14071619
M3 - Review article
C2 - 35406390
AN - SCOPUS:85126979953
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 7
M1 - 1619
ER -